drug · small molecule
capsaicin
Marketedupdated 3mo agoby Grunenthal GmbH🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2Small molecule drug with a maximum clinical stage of Approval (across all indications), with 12 approved and 31 investigational indications.
targets
Transient receptor potential cation channel subfamily V member 1
all catalysts(0)
nothing on the calendar yet
Trials studying capsaicin
- —Observational Study to Evaluate the Efficacy of Sustained QUTENZA® Use in Painful Diabetic Peripheral Neuropathy
- phase3Comparison of Qutenza (8% Capsaicin) With a Low-dose Capsaicin for Treatment of Nerve Pain After Surgery
- phase3Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy
- —Qutenza 8% Capsaicin Topical System for the Treatment of Neuropathic Axial Lower Back Pain and Lumbosacral Radiculopathy
- EP1Exploring the Benefit of Topical Capsaicin in Treating Pain From Chemo-induced Peripheral Neuropathy: a Longitudinal Single Center Pilot Study
- N/ATo Check Dermatological Safety of Test Products by 24 Hours Patch Testing
- phase4Capsaicin in Digital Osteoarthritis Versus Control
- phase1A Study to Evaluate Laser Speckle Contrast Imaging to Assess Changes in Chemical Agent-Induced Skin Blood Flow in Healthy Participants (MK-0000-420)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 15, 2028
~2.3 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (2)
- Mar 26, 2030formulationUS 88219203.6y
- Dec 15, 2028formulationUS 92269032.3y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 37m ago
Found something off?
comments(0)
5-min edit window · permanent after that